Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy - Wikidata - wikimedia - TriplyDB

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

http://www.wikidata.org/entity/Q35805813

about

Dietary interventions to extend life span and health span based on calorie restriction Effect of whole-body vibration for 3 months on arterial stiffness in the middle-aged and elderly.Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE Arterial stiffness and cardiovascular therapy Mechanisms of vascular aging: new perspectives.Role for glyoxalase I in Alzheimer's disease.Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.Clinical applications of arterial stiffness: therapeutics and pharmacology.Aminoguanidine prevents age-related aortic stiffening in Fisher 344 rats: aortic impedance analysis.Aminoguanidine prevents age-related deterioration in left ventricular-arterial coupling in Fisher 344 rats.Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects Age-related vascular stiffening: causes and consequences.Novel therapeutic strategies for reducing arterial stiffness Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats.Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats.Dietary advanced glycation end products and aging.Antihypertensive drugs and arterial stiffness.Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease.Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes.Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy Role of advanced glycation end products in cardiovascular disease.Elastin in large artery stiffness and hypertension.An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness.Fracture mechanics of collagen fibrils: influence of natural cross-links.The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy.The action of aminoguanidine on the liver of trained diabetic rats Role of arterial stiffness in cardiovascular disease.A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease Vascular compliance in the cardiometabolic syndrome.Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.Aminoguanidine impedes human pancreatic tumor growth and metastasis development in nude mice.Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice.Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.Quantitative blood flow measurements in the small animal cardiopulmonary system using digital subtraction angiography.Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes.Some mechanical aspects of arterial aging: physiological overview based on pulse wave analysis.RAGE biology, atherosclerosis and diabetes.Kidney aging--inevitable or preventable?Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.

P2860

Q24595003-4BD5D2CA-3C27-4818-AB0B-6F59EE5E255F Q33633319-672DFE99-1886-4A84-91D2-37F31793BAA1 Q33894738-DD6AA848-82A3-4A24-88C0-30E7445FD090 Q34079790-1FC88D75-5685-4ABB-8087-CD60BE0EAC0D Q34179571-79426709-5EFC-4499-B0C3-86ECCB13362B Q34336935-78077D1B-C5E2-4482-8880-D35BF5C9E9E9 Q34481838-558A9744-B809-46E2-97FE-CE6BF466021B Q34647819-D1F4992A-1FE5-45FA-9D0E-BCC6F2F3DD8D Q35045662-8802659E-2648-42B1-AE00-1E878E06F892 Q35047489-10AD2AD0-C353-4565-A2B7-7D0A07E60496 Q35083863-7AED86FA-444E-461B-9EFA-E8AA1A33FD89 Q35409645-A159835A-CAA1-4F1D-A12E-22C2EA13A670 Q35546271-53575E1C-D0A7-4F4F-8AEC-AF77B3DC7F3B Q35546284-BF484E67-3365-49E8-B89A-316C301ECBE5 Q35566544-44103AC3-3CB8-4951-9060-80C9C3F5A299 Q35670859-76117379-14B0-412A-9375-1486A2C46A03 Q35696484-4622EBC9-2C4F-44F7-A08A-A52EEE7D2ABA Q35796793-3D0394DD-2648-49AC-92BA-C53BE77EC0B0 Q35830289-ED4F7B0F-7DD5-48AC-8518-B02789EE97F8 Q35887541-5BB324B9-F855-4C57-9930-98CA619F1296 Q35929112-3CC12F8D-908F-4B7C-B3AA-70034A2CC7C0 Q36059927-9B593454-B01D-4FB5-B9F5-BCE0576F7045 Q36567296-4DF52E1C-01B9-4B14-8E56-911EF234EDC4 Q36832994-3EE2EF2E-4857-4E4B-BBFD-AFBE9BA75449 Q36903573-E9139650-F33E-4562-A2C0-11969A433D25 Q36904452-67428041-DBEA-4EE2-AD9C-7F23FBFC8053 Q37066216-F0E25CC5-5D23-4EE0-A722-8C0E68545AE5 Q37082512-078C4239-5DEB-4BF6-B29F-797C6C78C110 Q37097143-11A4D76F-F781-4387-A66B-698BA5DDFDA5 Q37104540-66831214-D450-4970-965B-C55626DC2DA8 Q37120232-66AA6097-1F62-4A65-9D6F-47BBE261412C Q37127122-3F83D302-B964-4E19-AEB8-18E3734159E1 Q37370688-B44EA4CA-B467-4583-B07C-02F06C8439DB Q37373486-9115471E-9550-46EB-A5B0-028592ED23FE Q37428394-EB2EDBCA-B020-471D-A464-57C784D20A1B Q37499860-E31D7499-DD60-4608-AE75-2D10B882C28D Q37539464-BE3DCB4E-968D-400B-B6DD-F7413792B70C Q37860348-D513E9AD-B207-4FF9-96A7-41CCBEBCBF73 Q37913979-A32B50C5-7D6B-46B0-97E9-B7E7FD6A8B24 Q38096444-AAC24D36-446D-4155-841E-970BFD0F8E28

P2860

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

http://www.wikidata.org/entity/Q35805813

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

@ast

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

@en

type

label

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

@ast

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

@en

prefLabel

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

@ast

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

@en

P1433

Q35805813-29BDC1BF-CD6F-44EF-9036-C30DC3D813C0

P1476

Q35805813-0A4B7DFB-BEDF-4566-B99D-5BE500AB5461

P2093

Q35805813-233310A3-8812-42CE-B84F-0C23752C7490

Q35805813-55612CFB-2F54-4C47-9807-789573971D3C

Q35805813-5F0F3D4F-4E98-4404-AB27-2FBCDD26E270

Q35805813-B65C02C9-D7EF-44E9-8425-FFF06FC6377C

Q35805813-DDC5377A-03F3-41CC-A3FB-B8AA43439216

Q35805813-ED82A635-DBF6-4B41-BC54-5D50DA811A52

P2860

Q35805813-0AD11CE5-DEAB-4602-9B92-935A81EBF211

Q35805813-0EA0BEC9-1922-467B-8A50-B4E36779E3FE

Q35805813-25F44886-257E-4AE7-82B0-9DD74FB7CA2F

Q35805813-29BED0D3-B7B6-49E5-90F9-925A37C93B4D

Q35805813-35625DE7-C668-4632-B384-7D41352B6C6A

Q35805813-41380A0E-0537-40DF-A821-9ACE07DE85D1

Q35805813-456B6641-5387-4356-8D5E-7095F1BE1375

Q35805813-51A9D49F-2A5F-44EF-9354-EDDCF15B4427

Q35805813-5CD95914-548E-4CF8-8A13-AFE3867665AE

Q35805813-6D5B21F6-CFFF-468B-8099-E8977193C2CE

P304

Q35805813-FE904BB8-73DD-486D-8377-E9726B4CC296

P31

Q35805813-932DD823-FE3C-4AAA-A802-0FC2F6153C07

P356

Q35805813-012E6CF0-BB6F-4853-8910-5A75FE26DEC8

P407

Q35805813-5C585BAE-2572-455F-AAD9-505A115ACA70

P433

Q35805813-99540559-6466-4429-A9E9-3A2E31E7BAE0

P478

Q35805813-A7CC0AA2-122C-4451-8AF8-837F6612AF90

P50

Q35805813-50305843-54CE-4CCB-B4F9-958705697695

P577

Q35805813-06B2EAE3-7ECB-4D35-8A2B-8BF7BDABA708

P5875

Q35805813-0A6D8160-D60A-4ED5-A7F3-9DD1E281A735

P698

Q35805813-8966846E-2D1B-43B2-A133-7946A2FC207F

P932

Q35805813-4B5DBE30-23CF-438B-8DB3-FBD16515C9FF

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

@en

P2093

A Tedgui

http://www.w3.org/2001/XMLSchema#string

B Corman

http://www.w3.org/2001/XMLSchema#string

B I Levy

http://www.w3.org/2001/XMLSchema#string

D Heudes

http://www.w3.org/2001/XMLSchema#string

M Duriez

http://www.w3.org/2001/XMLSchema#string

P Poitevin

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine

Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats

Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy.

Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat.

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.

Comparison of aortic intima and inner media in young adult versus aging rats. Stereology in a polarized system

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor

P304

1301-1306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.95.3.1301

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Bruneval

P577

1998-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235613855

http://www.w3.org/2001/XMLSchema#string

P698

9448326

http://www.w3.org/2001/XMLSchema#string

P932

18752

http://www.w3.org/2001/XMLSchema#string